Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Vaccinex, Inc. - Common Stock (NQ:VCNX)

1.410 UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 17, 2024 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	0
Open	1.410
Bid (Size)	1.320 (1)
Ask (Size)	1.460 (2)
Prev. Close	1.410
Today's Range	1.410 - 1.410
52wk Range	N/A - N/A
Shares Outstanding	65,941,086
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer’s Association International Conference in London on July 13, 2026

July 08, 2026

This first-in-class differentiated approach will be highlighted during a Featured Research Session entitled Alzheimer's therapy: mechanisms beyond amyloid

From Vaccinex, Inc.

Via GlobeNewswire

Vaccinex Reports 2025 Annual Financial Results

April 29, 2026

From Vaccinex, Inc.

Via GlobeNewswire

Performance

More News

Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease

December 23, 2025

From Vaccinex, Inc.

Via GlobeNewswire

VCNX Stock Earnings: Vaccinex Reported Results for Q2 2024 ↗

August 14, 2024

Via InvestorPlace

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

May 27, 2025

From Vaccinex, Inc.

Via GlobeNewswire

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)

April 21, 2025

From Vaccinex, Inc.

Via GlobeNewswire

Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

March 07, 2025

From Vaccinex, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

December 17, 2024

Via Benzinga

Vaccinex Faces Nasdaq Delisting: What's Going On With The Stock? ↗

December 17, 2024

Via Benzinga

Crude Oil Down Over 1%; US Industrial Production Declines In November ↗

December 17, 2024

Via Benzinga

Dow Dips Over 200 Points; US Retail Sales Top Estimates ↗

December 17, 2024

Via Benzinga

Vaccinex Announces Receipt of Delisting Notification from Nasdaq

December 17, 2024

From Vaccinex, Inc.

Via GlobeNewswire

Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 18, 2024

From Vaccinex, Inc.

Via GlobeNewswire

Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC

November 07, 2024

From Vaccinex, Inc.

Via GlobeNewswire

Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting

November 05, 2024

From Vaccinex, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

November 01, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 31, 2024

Via Benzinga

Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain

October 31, 2024

From Vaccinex, Inc.

Via GlobeNewswire

Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024

October 24, 2024

From Vaccinex, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

October 15, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 10, 2024

Via Benzinga

What's Going On With Vaccinex Stock Wednesday? ↗

September 18, 2024

Via Benzinga

Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds

September 18, 2024

From Vaccinex, Inc.

Via GlobeNewswire

Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership

August 14, 2024

From Vaccinex, Inc.

Via GlobeNewswire

Around $3M Bet On This Energy Stock? Check Out These 3 Stocks Insiders Are Buying ↗

August 02, 2024

Via Benzinga

Frequently Asked Questions

Is Vaccinex, Inc. - Common Stock publicly traded?

Yes, Vaccinex, Inc. - Common Stock is publicly traded.

What exchange does Vaccinex, Inc. - Common Stock trade on?

Vaccinex, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Vaccinex, Inc. - Common Stock?

The ticker symbol for Vaccinex, Inc. - Common Stock is VCNX on the Nasdaq Stock Market

What is the current price of Vaccinex, Inc. - Common Stock?

The current price of Vaccinex, Inc. - Common Stock is 1.410

When was Vaccinex, Inc. - Common Stock last traded?

The last trade of Vaccinex, Inc. - Common Stock was at 12/17/24 04:00 PM ET

What is the market capitalization of Vaccinex, Inc. - Common Stock?

The market capitalization of Vaccinex, Inc. - Common Stock is 92.98M

How many shares of Vaccinex, Inc. - Common Stock are outstanding?

Vaccinex, Inc. - Common Stock has 93M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.